A critical review of midazolam 10 mg autoinjector for the treatment of convulsive status epilepticus in adults

Introduction: Status epilepticus is a neurological emergency in which rapid treatment is essential to reduce morbidity and mortality. Delays in establishing intravenous access frequently hinder timely benzodiazepine administration, creating a critical need for fast, reliable, and user-friendly non-IV rescue therapies. The midazolam 10 mg autoinjector was developed to address these operational barriers and improve prehospital seizure management. Areas covered: This review examines the pharmacology, clinical efficacy, safety, and regulatory status of the midazolam autoinjector, drawing on published studies of intramuscular midazolam, pharmacokinetic evaluations of autoinjector formulations, and regulatory documents supporting its approval. Expert opinion: The midazolam autoinjector offers a meaningful advance in the treatment of status epilepticus by enabling rapid, consistent intramuscular delivery without preparation. Its design directly addresses the practical limitations of existing therapies and is likely to encourage adoption in prehospital and other time-critical settings. As emergency care increasingly prioritizes early intervention, autoinjector-based benzodiazepines are poised to play an expanding role in modern seizure-rescue strategies.